Treatment of idiopathic juxtafoveolar retinal telangiectasis with bevacizumab (Avastin);Behandlung idiopathischer juxtafoveolärer retinaler teleangiektasien mit bevacizumab (Avastin)

Klinische Monatsblatter fur Augenheilkunde

Volumn 224, Issue 10, 2007, Pages 787-790

  Schulze, Stephan ^a   Mennel, S ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Bevacizumab; Juxtafoveolar telangiectasis; Macular edema; VEGF

Indexed keywords

BEVACIZUMAB;

ARTICLE; CASE REPORT; CLINICAL FEATURE; FLUORESCENCE ANGIOGRAPHY; HUMAN; IDIOPATHIC DISEASE; JUXTAFOVEOLAR RETINA TELANGIECTASIA; RETINA DISEASE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FOVEA CENTRALIS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; RETINA; RETINAL DISEASES; TELANGIECTASIS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VITREOUS BODY;

EID: 35948967202     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963491     Document Type: Article

References (11)

1. Alldredge CD, Garretson BR. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003; 23: 113-116
2. Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 1993; 100: 1536-1546
3. Jorge R, Costa RA, Calucci D et al. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes's Arch Clin Exp Ophthalmol 2006 DOI 10.1007/s00417-006-0468-2
4. Koizumi H, Iida T, Maruko I. Morphological features of group 2A idiopathic juxtafoveolar retinal telangiectasis in three-dimensional optical coherence tomography. Am J Ophthalmol 2006; 142: 340-343
5. Li KKW, Goh TYH, Parsons H et al. Use of intravitreal triamcinolon acetonide injection in unilateral idiopathic juxtafoveal telangiectasis. Clin Experiment Ophthalmol 2005; 33: 542-544
6. McAllister KA, Grogg KM, Johnson DW et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8: 345-351
7. Mennel S, Hoerle S, Meyer CH. Photodynamic therapy in symptomatic parafoveal telangiectasia secondary to Osler-Rendu-Weber disease. Acta Ophthalomol Scand 2006; 84: 273-275
8. Park DW, Schatz H, McDonald HR et al. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Opthalmology 1997; 104: 1838-1846
9. Potter MJ, Szabo SM, Sarraf D et al. Photodynamic therapy for subretinal neovascularization of type 2A idiopathic juxtafoveolar retinal telangiectasis. Can J Ophthalmol 2006; 41: 34-37
10. Spaide RF, Laud K, Fine H et al. Intravitreal bevacuzimab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-390
11. Surguch V, Gamulescu MA, Gabel VP. Optical coherence tomography findings in idiopathic juxtafoveolar retinal telangiectasis. Graefes's Arch Clin Exp Ophthalmol 2006 DOI 10.1007/s00417-006-0432-1